BEN E. GREENWELL, PH.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: It is regrettable that exquisitely designed and executed clinical trials sometimes fall prey to logistics problems that limit their scope. Such appears to have been the case with the National Cooperative Gallstone Study (NCGS) (1), which was conceived in 1972, begun in 1976, completed in 1980, and first reported in 1981. Soon after the protocol involving fixed doses of 375 mg or 750 mg per day was finalized in March 1975, investigators at Mayo Clinic (2) and at Guy's Hospital, London (3), reported retrospective analyses of their data indicating that the optimal dose for chenodiol (chenodeoxycholic acid)
GREENWELL BE. Prospects for Chenodiol Therapy. Ann Intern Med. 1981;95:659–660. doi: https://doi.org/10.7326/0003-4819-95-5-659_2
Download citation file:
Published: Ann Intern Med. 1981;95(5):659-660.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use